Bioventix's Total Assets for the quarter that ended in Dec. 2025 was $17.45 Mil.
Warning Sign:
If a company builds assets at 7.8% a year, faster than its revenue growth rate of 5.5% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Bioventix's average Total Assets Growth Rate was -1.70% per year.
During the past 3 years, the average Total Assets Growth Rate was 3.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 7.80% per year.
During the past 10 years, the average Total Assets Growth Rate was 10.70% per year.
During the past 13 years, Bioventix's highest 3-Year average Total Assets Growth Rate was 26.30%. The lowest was 3.70%. And the median was 13.75%.
Total Assets is connected with ROA %. Bioventix's annualizedROA % for the quarter that ended in Dec. 2025 was 55.61%. Total Assets is also linked to Revenue through Asset Turnover. Bioventix's Asset Turnover for the quarter that ended in Dec. 2025 was 0.47.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Bioventix's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Bioventix Total Assets Related Terms
Bioventix Total Assets Historical Data
* Premium members only.
The historical data trend for Bioventix's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Bioventix's Total Assets for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioventix (BVNXF) has a Total Assets of $17.45 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Bioventix and its competitors.
Is Bioventix's Total Assets too high?
Bioventix's current Total Assets is $17.45 Mil. Overall, Bioventix has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Bioventix's Total Assets compare to VRTX and REGN?
Bioventix's Total Assets of $17.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Bioventix and its competitors. Bioventix's current Total Assets is $17.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventix stock overvalued right now?
Bioventix (BVNXF) has a current Total Assets of $17.45 Mil. The stock's GF Value™ is $32.94, compared to a current price of $14.71 — trading 55.3% below its estimated fair value. The current Total Assets is $17.45 Mil. Bioventix's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Bioventix (BVNXF), the current Total Assets is $17.45 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioventix (BVNXF) Overvalued in 2026?
Based on GuruFocus' analysis, Bioventix stock appears to be undervalued.
The current stock price of $14.71 is trading 55.3% below its estimated GF Value™ of $32.94.
Key valuation signals for BVNXF:
Total Assets: $17.45 Mil
GF Value™: $32.94 vs. price of $14.71 (55.3% below fair value)
No single metric tells the full story. See the BVNXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
62GF Score
Get the complete analysis for BVNXF
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BVNXF has been successfully added to your 
